Amundi Cuts Stock Position in Thermo Fisher Scientific Inc. $TMO

Amundi trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 10.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,813,091 shares of the medical research company's stock after selling 203,169 shares during the quarter. Amundi owned 0.49% of Thermo Fisher Scientific worth $909,011,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of TMO. High Note Wealth LLC lifted its position in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after acquiring an additional 29 shares in the last quarter. Swiss RE Ltd. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $28,000. Kilter Group LLC purchased a new position in shares of Thermo Fisher Scientific in the second quarter worth $25,000. Legacy Wealth Managment LLC ID lifted its holdings in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after purchasing an additional 22 shares in the last quarter. Finally, Birchwood Financial Partners Inc. bought a new stake in Thermo Fisher Scientific in the 4th quarter worth about $29,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a report on Friday, July 24th. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 target price for the company. KeyCorp restated an "overweight" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research report on Monday, July 6th. Finally, Piper Sandler raised their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a research report on Monday, July 27th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $619.41.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $612.75 on Monday. The firm's 50 day simple moving average is $570.91 and its two-hundred day simple moving average is $515.17. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company has a market capitalization of $226.56 billion, a P/E ratio of 32.96, a P/E/G ratio of 2.57 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $647.00.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company's stock, valued at approximately $77,982,284.75. This represents a 7.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the sale, the chief operating officer directly owned 24,651 shares in the company, valued at approximately $13,927,815. The trade was a 1.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,768 shares of company stock valued at $44,122,820 in the last ninety days. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source